The EU pays more than 1 billion euros for Remdesivir
The European Union has agreed to pay more than 1 billion euros to Gilead for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication.
** This post was originally published on October 13, 2020 **